Microsite es: . Grupo:

Gold (I)-Based Compounds and their Potential as Chemo- and Targeted- therapeutics for Renal and Breast Cancer

Thursday, August 08, 2019 - 12:00
Place: 
Donostia International Physics Center
Who: 
Maria Contel, Brooklyn College, The City University of New York
Source Name: 
DIPC

Gold compounds are emerging as promising anticancer chemotherapeutics with a gold(I) compound Auranofin (a thiolate containing the [AuPEt3]+ fragment) being evaluated in clinical trials. Our group at Brooklyn College has reported on the preparation of heterometallic complexes containing titanocenes [TiCp2] or ruthenium(II) arene derivatives [RuCl2(p-cymene)(dppm)] and gold(I)-phosphane or gold(I)-N-heterocyclic NHC-carbene fragments and their potential as chemotherapeutics against renal or colorectal cancers (including studies of their efficacy in vivo, pharmacokinetics, histopathology and mechanisms). We will provide a brief overview on this topic. We are also working on strategies for the delivery of metal-based drugs so that they can be efficiently released at the specific tumor site to improve selectivity, bioavailability and blood circulation times. We will report on delivery vehicles for gold(I)-based cytotoxic agents (containing phosphanes and NHC-carbene ligands) consisting on: a) “smart” peptide nanocarriers, and b) antibodies such as trastuzumab. We will describe synthetic strategies to obtain antibody-drug conjugates and to encapsulate gold compounds in MMP-9 responsive peptide-based nanocarriers. Results for cellular viability assays in human renal and breast cancer cell lines and non-cancerous cell lines to highlight the tumor targeting properties of these systems will be discussed.
Host: Luca Salassa

x
We use third party cookies to improve our services and tailor the website to your surfing habits. By continuing to browse the site, you are agreeing to our use of cookies policy. Further information on the use of cookies.